RADIONUCLIDE WHOLE BODY BONE SCAN

DATE: 4/20/2006

PROCEDURE:  Following IV administration of technetium-99m methylene diphosphonate (MDP), scans of the entire skeleton were obtained in the anterior and posterior projections.

RADIOPHARMACEUTICAL DOSE:  [25] mCi

CLINICAL HISTORY: The patient is a [...]-year-old [fe]male with a history of [...]. The patient is referred for evaluation of possible osseous metastatic disease. The patient is referred for follow-up of osseous metastatic disease.

CORRELATIVE STUDIES: None.

COMPARISON: None.

FINDINGS: 

There is increased tracer activity observed in [...] that are consistent with degenerative changes.  The remainder of the axial and appendicular skeleton demonstrates normal tracer uptake. There is normal tracer activity in both kidneys and in the urinary bladder.

CONCLUSIONS:

Normal study showing no evidence of osseous metastatic disease.

No focus of increased tracer uptake is identified that would be consistent with osseous metastasis.

There are no significant changes when compared to the prior study.

No new foci of abnormally increased tracer activity are identified.

Focally increased activity at the xxx remains unchanged. Plain films for the abnormalities described above were not suggestive for metastatic disease. Given stability and negative plain film findings, the likelihood of metastasis is exceedingly low.

The mottled appearance of the abnormally increased tracer uptake in the xxx may be associated with xxx.  Plain X-rays of the xxx are recommended.

Thank you for referring this patient to the UCLA Nuclear Medicine Clinic.

I, [...], M.D., Ph.D., have reviewed this Nuclear Medicine study personally, and am in full agreement with the findings of the report presented here.